Latest atopic dermatitis Stories
MINNEAPOLIS, July 26, 2011 /PRNewswire/ -- Nearly every parent has experienced this distressing situation: the baby who wakes, irritable and uncomfortable, drenched in perspiration. Unfortunately, the resulting moisture then causes babies' sensitive skin to become irritated and itchy. For those parents whose children have eczema or severely sensitive skin, an overheated baby can lead to a cycle of itching and scratching which only exacerbates the sensitivity of their child's skin. To view...
MAPLE GROVE, Minn., July 11, 2011 /PRNewswire/ -- Today Upsher-Smith Laboratories, Inc. announced the launch of Trianex(TM) 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment. Trianex(TM) combines triamcinolone, the No. 1 prescribed type of topical corticosteroid,(1) with a pleasing cream-like base to relieve inflammation and itching in skin conditions that respond to treatment with corticosteroids,...
FLORHAM PARK, N.J., May 26, 2011 /PRNewswire/ -- Today, Gerber Products Company, a part of the Nestle family, announced that Gerber® Good Start® milk-based formulas are the first and only infant formulas that meet the criteria for a qualified health claim. Specifically, the FDA concluded that current scientific evidence is appropriate for consideration of a qualified health claim relating to a reduced risk of atopic dermatitis. (Logo:...
Atopic dermatitis is a form of eczema that is caused by an inappropriate inflammatory response in the skin. Many children with atopic dermatitis also have food allergies, and skin contact with food allergens can make their atopic dermatitis worse. It is unclear why this occurs, but it has been suggested that immune cells known as T cells that are sensitized by exposure to food allergens in the gut are responsible. Raif Geha and colleagues, at Harvard Medical School, Boston, have now generated...
LUXEMBOURG, March 10, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal characteristics for topical application (high...
CUMBERLAND, R.I., Feb. 22, 2011 /PRNewswire/ -- Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of the HylatopicPlus-Aurstat(TM) Kit. The kit provides two products within one package: HylatopicPlus(TM) Emollient Foam indicated to manage and relieve burning, itching and pain that can accompany skin dermatoses such as atopic dermatitis (eczema) and...
The first study of its kind in the world "” involving 336 children aged between six months and 16 years old "” has shown that installing a water softener for three months brings no additional relief for eczema sufferers.Up to one fifth of all children of school age have eczema, along with about one in 12 of the adult population. Anecdotal reports from patients have suggested that hard water may worsen atopic eczema. Population surveys have also suggested a possible link between atopic...
SAN FRANCISCO, Feb. 16, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Oculus Innovative Sciences, Inc., (Nasdaq: OCLS) and maintains its $3.81 target price. Ross Silver, Principal Analyst at Vista Partners stated, "Oculus is growing significantly as evidenced by their revenue growth of approximately 40% in each of the past two years. In addition, management has provided revenue guidance of $45-$60M in fiscal year 2013, a six fold increase from revenues...
OXFORD, England, February 9, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales. PAP-1 is one of the most...
Preventative tips may help minimize risks NEW ORLEANS, Feb. 4, 2011 /PRNewswire-USNewswire/ -- What may start as a seemingly harmless day of gardening or yard work can quickly take a turn for the worse when common plants make their mark on the skin, causing a host of mild to even severe skin reactions. That is why dermatologists are arming outdoor enthusiasts with preventative tips to keep these perils of the great outdoors at arm's length. Speaking today at the 69th Annual Meeting of the...
